Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, January 13, 2026
Veristat announced that Kim McLean Boericke has been named Chief Executive Officer (CEO). Boericke, an experienced executive with decades of leadership and operational experience in the clinical research industry, succeeds Patrick Flanagan. After 13 ...
read more
Tuesday, November 01, 2016
Veristat, a full service consultative Clinical Research Organization (CRO), has announced the formal launch of its Strategic Decision Consulting service offering to help pharmaceutical, biotechnology and medical device firms solve the unique and ...
read more
Veristat, a full service Clinical Research Organization (CRO), is expanding its clinical research offerings into Europe through the acquisition of UK-based CRO, Spero Oncology. Spero Oncology is a UK-based CRO specializing in providing clinical ...
read more
Veristat, a global clinical research organization (CRO), announced the expansion and strengthening of its service capabilities by acquiring SFL (Solutions for Life Sciences). With headquarters in Basel, Switzerland and several European affiliates, ...
read more
Thursday, October 19, 2023
Veristat, a scientific full-service clinical research organization (CRO) and consultancy acquired Instat Clinical Research, a biometrics CRO with a 20-year track record of transforming complex data into precise study results.
read more
Thursday, September 25, 2025
Verismo Therapeutics, a clinical-stage CAR T company developing a novel KIR-CAR platform technology, announced the successful manufacture of its first clinical cell product using lentiviral vector supplied by Miltenyi Bioindustry, a dedicated CDMO ...
read more
Monday, December 30, 2019
Verily is partnering with Emory Healthcare to deploy new solutions to help improve cost-effectiveness, operational efficiency and quality.
read more
Thursday, January 09, 2020
Verastem announced a global licensing agreement with Chugai Pharmaceutical.
read more
Wednesday, August 13, 2025
Veranova announced that a routine current Good Manufacturing Practice (cGMP) surveillance inspection of Veranova’s Devens, Massachusetts site, completed by the FDA New England District on July 31, 2025, concluded without any Form 483s and with a “No ...
read more
Veranova announced a strategic investment to establish state-of-the-art bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus.
read more
Veranova announced the move of its corporate headquarters to its Devens, Massachusetts facility, one of the company’s principal sites for manufacturing and development.
read more
Veranova’s subsidiary, Macfarlan Smith, announced a proposal to close its Annan, UK facility.
Over the last several months, Veranova conducted a review of its manufacturing capacity relative to customer needs and market trends across its product ...
read more
Veranova announced the appointment of Elizabeth Rebeil as Global Vice President of Supply Chain and Operational Excellence. Ms. Rebeil brings more than 20 years of experience in supply chain management and continuous improvement within the ...
read more
Monday, September 29, 2025
Veranova announced the appointment of Joe Torres-Ocasio as Senior Vice President and Chief Operating Officer (COO). He will lead Veranova’s global operations across its manufacturing network in Europe and North America, and will also oversee the ...
read more
Veranova announced the appointment of Thomas Rohrer as Vice President of Bioconjugation. This appointment follows a recently announced investment to establish cGMP bioconjugation capabilities at its Devens, MA site.
read more